Resurgence of Bispecific Antibodies

Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

Volumn , Issue , 2013, Pages 529-543

  Baeuerle, Patrick A ^a   Raum, Tobias ^a  

^a Amgen Research GmbH   (Germany)

Author keywords

Asymmetric IgG like; Bispecific constructs; Bispecific, resurgence; Multifunctional antibodies; Right format selection

Indexed keywords

EID: 84878898615     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118354599.ch35     Document Type: Chapter

References (90)

1. Milstein C, Cuello AC. (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305, 537-540.
2. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol. 155, 219-225.
3. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized Phase II/III trial. Int. J. Cancer 127, 2209-2222.
4. Brennan M, Davison PF, Paulus H. (1985) Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229, 81-83.
5. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, et al. (1995) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpress the proto-oncogene HER-2/neu. J. Clin. Oncol. 13, 2281-2292.
6. Staerz UD, Kanagawa O, Bevan MJ. (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314, 628-631.
7. Corvalan JR, Smith W. (1987) Construction and characterization of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids. Cancer Immunol. Immunother. 24, 127-132.
8. Carter P. (2001) Bispecific human IgG by design. J. Immunol. Methods 248, 7-15.
9. Kufer P, Lutterbuese R, Baeuerle PA. (2004) A revival of bispecific antibodies. Trends Biotechnol. 22, 238-244.
10. Müller D, Kontermann RE. (2007) Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr. Opin. Mol. Ther. 9, 319-326.
11. Van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. (2007) Antiinflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554-1557.
12. Mouquet H,Scheid JF,Zoller MJ,Krogsgaard M,Ott RG,Shukair S, et al. (2010) Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467, 591-595.
13. Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM. (2009) Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J. Exp. Clin. Cancer Res. 14, 18.
14. Seimetz D, Lindhofer H, Bokemeyer C. (2010) Development and approval of the trifunctional antibody catumaxomab (anti- EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev. 36, 458-467.
15. Kiewe P, Hasmüller S, Klahert S, Heinrigs M, Rack B, Marme A, et al. (2008) Clin. Cancer Res. 12, 3085-3091.
16. Ruf P, Kluge M, Jäger M, Burges A, Volovat C, Heiss MM, et al. (2010) Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br. J. Clin. Pharmacol. 69, 617-625.
17. Ridgway JB, Presta LG, Carter P. (1996) "Knobs-in-holes" engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617-621.
18. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al. (2010) Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signalling. J. Biol. Chem. 285, 20850-20859.
19. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. (2010) Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285, 19637-19646.
20. Wranik B. (2010) Keystone Conference on Advances in Biopharmaceuticals, Keystone, CO, 2010 Jan 10.
21. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al. (2010) SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng. Des. Sel. 23, 195-202.
22. Klein C. (2010) Antibody Engineering Conference, San Diego, CA, 2010 Dec 2010.
23. Throsby M. (2010) Third Annual Antibody Engineering and Therapeutics Asia, Shanghai, China, 2010 Nov 11.
24. Schuurman J. (2010) Third Annual Antibody Engineering and Therapeutics Asia, Shanghai, China, 2010 Nov 11.
25. Ward ES, Güssow D, Griffiths AD, Jones PT,Winter G. (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341, 544-546.
26. Hamblin P. (2010) Sixth Annual PEGSummit, Boston, MA, 2010 May 20-21.
27. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614.
28. Fuh G. (2010) 25th Annual Meeting of International Society for Biological Therapy of Cancer, Washington, 2010 Oct 2.
29. Lum LG, Davol PA. (2005) Retargeting T cells and immune effector cells with bispecific antibodies. Cancer Chemother. Biol. Response Modif. 22, 273-291.
30. Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, et al. (2006) Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin. Cancer Res. 12, 569-576.
31. Lum L. (2010) Sixth Annual PEGSummit, Boston, MA, 2010 May 20-21.
32. Fitzgerald K. (2010) Sixth Annual PEGSummit, Boston, MA, 2010 May 20.
33. Gavrilyuk JI, Wuellner U, Salahuddin S, Goswami RK, Sinha SC, Barbas CF, 3rd. (2009) An efficient chemical approach to bispecific antibodies and antibodies of high valency. Bioorg. Med. Chem. Lett. 19, 3716-3720.
34. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al. (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain Immunoglobulin. Nat. Biotech. 25, 1290-1297.
35. Ghayur T. (2010) Drug Discovery and Development Week, Burlingame, CA, 2010 August 3.
36. Ludwig D. (2010) Drug Discovery and Development Week, Burlingame, CA, 2010 Aug 3.
37. Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P, Bohlen P, et al. (2003) Di-diabody: a tetravalent bispecific antibody molecule by design. J. Immunol. Methods 279, 219-232.
38. Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, et al. (2010) Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng. Des. Sel. 23, 115-127.
39. Michaelson JS, Dermarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, et al. (2009) Anti-tumor activity af stabilityengineered IgG-like bispecific antibodies targeting TRAILR2 and LT-betaR. MAbs 1, 128-141.
40. Scheuer W. (2010) The NCI-EORTC-AACR Meeting in Berlin, Germany, 2010 Nov 19.
41. Dinasi N. (2010) Sixth Annual PEGSummit, Boston MA, 2010 May 20-21.
42. Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, et al. (2006) Fucose removal from complex-type oligosaccharide enhances the antibodydependent cellular cytotoxicity of single-gene-encoded bispecific antibodies linked to the antibody constant domain. J. Biochem. 140, 359-368.
43. Lu H, Shi M, Wang M, Xie Z, Hu M, Yu M, et al. (2008) In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16. Cancer Biol. Ther. 7, 1744-1750.
44. Blankenship JW, Strobel S, Tan P, Grosmaire L, Simon A, Clark C, et al. (2009) Anti-CD79B x anti-DR SCORPION molecule: A single chain, bispecific immunotherapeutic with potent in vitro activity against B-cell lymphoma. Poster at 100th Annual Meeting of the American Association for Cancer Research, Abstract No. 5465.
45. Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, et al. (2010) A dual-targeting PDGFRbeta/ VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. MAbs 2, 20-34.
46. Johnson S. (2010) Drug Discovery and Development Week, Burlingame, CA, 2010 Aug 2-4.
47. Guo J. (2010) Third Annual Antibody Engineering and Therapeutics Asia, Shanghai, China, 2010 Nov 11.
48. Roopenian DC, Akilesh S. (2007) FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725.
49. Nimmerjahn F, Ravetch JV. (2008) Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47.
50. Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, et al. (2007) Treatment of non-small cell lung cancer oatients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a Phase I study. Cancer Immunol. Immunother. 56, 1637-1644.
51. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. (2006) Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103, 4005-4010.
52. Beckman RA, Weiner LM, Davis HM. (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109, 170-179.
53. Sheer J. (2010) The Sixth Annual PEGSummit in Boston, MA, 2010 May 20-21.
54. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. (2009) Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 113, 6161-6171.
55. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. (2010) Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin. Nucl. Med. 40, 190-203.
56. Schoonjans R,Willems A, Schoonooghe S, Fiers W, Grooten S, Mertens N. (2000) Fab chains as an efficient heterodimerization domain scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J. Immunol. 165, 7050-7057.
57. Schanzer JM, Fichtner I, Baeuerle PA, Kufer P. (2006) Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep- CAM expressing tumor cells. J. Immunother. 29, 477-488.
58. Humphreys D. (2010) Antibody Engineering Conference, San Diego, CA, 2010 Dec 8.
59. Nelson AL. (2010) Antibody fragments: hope and hype. MAbs 2, 77-83.
60. Mabry R, Snavely M. (2010) Therapeutic bispecific antibodies: the selection of stable single-chain fragments to overcome engineering obstacles. IDrugs 13, 543-549.
61. Huston JS, Mudgett-Hunter M, Tai MS, McCartney J, Warren F, Haber E, et al. (1991) Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol. 203, 46-88.
62. Todorovska A, Roovers RC, Dolezal, O, Kortt, AA, Hoogenboom, HR, Hudson, PJ. (2001) Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 248, 47-66.
63. Baeuerle PA, Kufer P, Bargou R. (2009) BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr. Opin. Mol. Ther. 11, 22-30.
64. Baeuerle PA, Reinhardt C. (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69, 4941-4944.
65. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. (2010) Complete remission after blinatumomab- induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia, October 14 [Epub ahead of print].
66. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-977.
67. Stein C, Kellner C, Kügler M, Reiff N, Mentz K, Schwenkert M, et al. (2010) Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br. J. Haematol. 148, 879-889.
68. Schubert I,Kellner C, Stein C,Kügler M, SchwenkertM, Saul D, et al. (2011)A single-chain triplebody with specificity forCD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs, 1, 3 [Epub ahead of print].
69. Guettinger Y, Barbin K, Peipp M, Bruenke J, Dechant M, Horner H, et al. (2010) A recombinant bispecific single-chain fragmentr variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells. J. Immunol. 184, 1210-1217.
70. Le Gall F, Reusch U, Little M, Kipriyanov SM. (2004) Effect of linker sequences between the antibody variable domains on the formation, stability, and biological activity of a bispecific tandem diabody. Protein Eng. Des. Sel. 17, 357-366.
71. Reusch U, Le Gall F, Hensel M, Moledenhauer G, Ho AD, Little M, et al. (2004) Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis ofmalignantBcells frompatients with chronic lymphocytic leukemia by autologous T cells. Int. J. Cancer 112, 509-518.
72. Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M. (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplanted human Hodgkin's tumors. Blood 94, 2562-2568.
73. Cochlovius B, Kipiriyanov SM, Stassar MJ, Schuhmacher J, Bener A, Moldenhauer G, et al. (2000) Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3CD19 tandem diabody, and CD28 costimulation. Cancer Res. 60, 4336-4341.
74. Johnson S, Burke S, Huang L, Gorlatov S, Li H,Wang H, et al. (2010) Effector cell recruitment with novel Fv-based dualaffinity retargeting proteins leads to potent tumor cytolysis and in vivo B-cell depletion. J. Mol. Biol. 399, 436-449.
75. Veri MC, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, et al. (2010) Therapeutic control ofBcell activationvia recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum. 62, 1933-1943.
76. Villani ME, Di Carli M, Donini M, Traversini G, Lico C, Franconi R, et al. (2008) Validation of a stable recombinant antibodies repertoire for the direct selection of functional intracellular reagents. J. Immunol. Methods 329, 11-20.
77. Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuss N, Müller D, et al. (2010) The effects of affinity and valency of an albuminbinding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng. Des. Sel. 23, 827- 834.
78. Noy R, Eppel M, Haus-Cohen M, Klechevsky E, Mekler O, Michaeli Y, et al. (2005) T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy. Expert Rev. Anticancer Ther. 5, 523-536.
79. Drummond D. (2010) Drug Discovery and Development Week, Burlingame, CA, 2010 August 2-4.
80. Zhu X, Wang L, Liu R, Flutter B, Li S, Ding J, et al. (2010) COMBODY: one-domain antibody multimer with improved avidity. Immunol. Cell Biol. 88, 667-675.
81. Shusterman SS, London, WB, Gillies SD, Hank, JA, Voss, SD, Seeger, RC, et al. (2010) Antitumor activity of Hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a children's oncology group (COG) Phase II study. J. Clin. Oncol. October 4 [Epub ahead of print].
82. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, et al. (2010) Eur. J. Cancer 46, 2926-2935.
83. Robinson MK, Alpaugh RK, Borghaei H. (2010) Naptumomab estefenatox: a new immunoconjugate. Expert Opin. Biol. Ther. 10, 273-279.
84. Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, et al. (2004) Individualized patient dosing in Phase I clinical trials: the role of escalation with overdose control in PNU-214936. J. Clin. Oncol. 22, 602-609.
85. Liddy N, Molloy PE, Bennett AD, Boulter JM, Jakobsen BK, Li Y. (2010) Production of a soluble disulfide-linked TCR in the cytoplasm of Escherichia coli trxB got mutants. Mol. Biotechnol. 45, 140-149.
86. Okazaki A, Shoji-Hosaka E, Nakamura K,Wakitani M, Uchida K, Kakita S, et al. (2004) Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J. Mol. Biol. 336, 1239-1249.
87. Bugelski PJ, Achuthanadam R, Capocascale RJ, Treacy G, Bouman-Thio E. (2009) Monoclonal antibody-induced cytokine- release syndrome. Expert Rev. Clin. Immunol. 5, 499-521.
88. Dohlsten M, Hedlund G, Kalland T. (1991) Staphylococcalenterotoxin- dependent cell-mediated cytotoxicity. Immunol. Today 12, 147-150.
89. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, et al. (2010) T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc. Natl. Acad. Sci. USA 107, 12605-12610.
90. Purbhoo MA, Irvine DJ, Huppa JB, Davis MM. (2004) T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 5, 524-530.